New molecular classifications of breast cancer
- PMID: 19729680
- DOI: 10.3322/caac.20029
New molecular classifications of breast cancer
Abstract
Traditionally, pathologic determinations of tumor size, lymph node status, endocrine receptor status, and human epidermal growth factor receptor 2 (HER2) status have driven prognostic predictions and adjuvant therapy recommendations for patients with early stage breast cancer. However, these prognostic and predictive factors are relatively crude measures, resulting in many patients being overtreated or undertreated. As a result of gene expression assays, there is growing recognition that breast cancer is a molecularly heterogeneous disease. Evidence from gene expression microarrays suggests the presence of multiple molecular subtypes of breast cancer. The recent commercial availability of gene expression profiling techniques that predict risk of disease recurrence as well as potential chemotherapy benefit have shown promise in refining clinical decision making. These techniques will be reviewed in this article.
(c) 2009 American Cancer Society, Inc.
Similar articles
-
Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.Adv Anat Pathol. 2009 Jul;16(4):204-15. doi: 10.1097/PAP.0b013e3181a9d4bf. Adv Anat Pathol. 2009. PMID: 19546609 Review.
-
Commercialized multigene predictors of clinical outcome for breast cancer.Oncologist. 2008 May;13(5):477-93. doi: 10.1634/theoncologist.2007-0248. Oncologist. 2008. PMID: 18515733 Review.
-
Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.Expert Rev Mol Diagn. 2007 May;7(3):269-80. doi: 10.1586/14737159.7.3.269. Expert Rev Mol Diagn. 2007. PMID: 17489734 Review.
-
MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.Cancer Treat Rev. 2009 Jun;35(4):328-34. doi: 10.1016/j.ctrv.2008.12.002. Epub 2009 Jan 25. Cancer Treat Rev. 2009. PMID: 19171434 Review.
-
Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy.Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1019s-1023s. doi: 10.1158/1078-0432.CCR-05-2296. Clin Cancer Res. 2006. PMID: 16467119
Cited by
-
Bone metastasis pattern in initial metastatic breast cancer: a population-based study.Cancer Manag Res. 2018 Feb 9;10:287-295. doi: 10.2147/CMAR.S155524. eCollection 2018. Cancer Manag Res. 2018. PMID: 29467583 Free PMC article.
-
Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.PLoS One. 2017 Nov 15;12(11):e0188068. doi: 10.1371/journal.pone.0188068. eCollection 2017. PLoS One. 2017. PMID: 29140993 Free PMC article.
-
Molecular characterization of breast cancer cell lines through multiple omic approaches.Breast Cancer Res. 2017 Jun 5;19(1):65. doi: 10.1186/s13058-017-0855-0. Breast Cancer Res. 2017. PMID: 28583138 Free PMC article.
-
Role of high mobility group A1 and body mass index in the prognosis of patients with breast cancer.Oncol Lett. 2017 Nov;14(5):5719-5726. doi: 10.3892/ol.2017.6963. Epub 2017 Sep 15. Oncol Lett. 2017. PMID: 29113200 Free PMC article.
-
Metastasis inhibition in breast cancer by _targeting cancer cell extravasation.Breast Cancer (Dove Med Press). 2019 Apr 18;11:165-178. doi: 10.2147/BCTT.S166725. eCollection 2019. Breast Cancer (Dove Med Press). 2019. PMID: 31114313 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous